Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC6019-0001 in transthyretin amyloid cardiomyopathy (Japan)
jRCT2061230027Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change in 6-minute walk test distance from baseline to week 52 and Change in NT-proBNP from baseline to week 52. Started Jul 2023; status: completed.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2061230027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230027.